• Sara J Brown.
• Wellcome Trust senior research fellow in clinical science and honorary consultant dermatologist, Skin Research Group, Ninewells Hospital and Medical School, Dundee, UK s.j.brown@dundee.ac.uk.
• Clin Med (Lond). 2016 Feb 1; 16 (1): 666966-9.

AbstractAtopic eczema is an itchy inflammatory skin disease with a chronic relapsing-remitting course; it has increased in prevalence in recent decades and now affects up to 25% of school-aged children in the developed world and up to 10% of adults. Recent advances in understanding the aetiology of eczema have focused interest on skin barrier dysfunction as a common precursor and pathological feature. In addition, genetically determined skin barrier dysfunction (associated with mutations in the gene encoding filaggrin) is known to predispose to multiple systemic atopic diseases. First-line treatments for atopic eczema focus on maintaining and repairing the skin barrier (emollients) and reducing inflammation (topical steroids); allergen and irritant avoidance are also important to achieve disease control. Second and third-line treatments include topical calcineurin inhibitors, ultraviolet light and systemic immunosuppressant therapies of which only ciclosporin is licenced for the treatment of atopic eczema in adults. Novel biological therapies are in phase II-III clinical trials.© Royal College of Physicians 2016. All rights reserved.

12 keywords...

hide…